Journal Article
. 2019 Dec;382(7).
doi: 10.1056/NEJMoa1914510.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi 1 Cristina Saura 1 Toshinari Yamashita 1 Yeon Hee Park 1 Sung-Bae Kim 1 Kenji Tamura 1 Fabrice Andre 1 Hiroji Iwata 1 Yoshinori Ito 1 Junji Tsurutani 1 Joohyuk Sohn 1 Neelima Denduluri 1 Christophe Perrin 1 Kenjiro Aogi 1 Eriko Tokunaga 1 Seock-Ah Im 1 Keun Seok Lee 1 Sara A Hurvitz 1 Javier Cortes 1 Caleb Lee 1 Shuquan Chen 1 Lin Zhang 1 Javad Shahidi 1 Antoine Yver 1 Ian Krop 1 DESTINY-Breast01 Investigators  
Affiliations
  • PMID: 31825192
  •     22 References
  •     56 citations

Abstract

Background: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.

Methods: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.

Results: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).

Conclusions: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Toshihiko Doi, Kohei Shitara, +14 authors, Kenji Tamura.
Lancet Oncol, 2017 Oct 19; 18(11). PMID: 29037983
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Yusuke Ogitani, Tetsuo Aida, +13 authors, Toshinori Agatsuma.
Clin Cancer Res, 2016 Mar 31; 22(20). PMID: 27026201
Highly Cited.
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1).
Matthew Sung, Xingzhi Tan, +12 authors, Frank Loganzo.
Molecular cancer therapeutics, 2017 Oct 22; 17(1). PMID: 29054985
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
Carla Ríos-Luci, Sara García-Alonso, +4 authors, Atanasio Pandiella.
Cancer Res, 2017 Jul 09; 77(17). PMID: 28687619
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Sandra M Swain, José Baselga, +12 authors, CLEOPATRA Study Group.
N Engl J Med, 2015 Feb 19; 372(8). PMID: 25693012    Free PMC article.
Highly Cited.
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Ana M Gonzalez-Angulo, Jennifer K Litton, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884543    Free PMC article.
Highly Cited.
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
Adedayo A Onitilo, Jessica M Engel, Robert T Greenlee, Bickol N Mukesh.
Clin Med Res, 2009 Jul 04; 7(1-2). PMID: 19574486    Free PMC article.
Highly Cited.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, +3 authors, W L McGuire.
Science, 1987 Jan 09; 235(4785). PMID: 3798106
Highly Cited.
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
Julien Marcoux, Thierry Champion, +5 authors, Sarah Cianférani.
Protein Sci, 2015 Feb 20; 24(8). PMID: 25694334    Free PMC article.
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
Frank Loganzo, Xingzhi Tan, +19 authors, Hans-Peter Gerber.
Molecular cancer therapeutics, 2015 Feb 04; 14(4). PMID: 25646013
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Takashi Nakada, Kiyoshi Sugihara, +2 authors, Toshinori Agatsuma.
Chem Pharm Bull (Tokyo), 2019 Mar 05; 67(3). PMID: 30827997
Highly Cited. Review.
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Yusuke Ogitani, Katsunobu Hagihara, +2 authors, Toshinori Agatsuma.
Cancer Sci, 2016 May 12; 107(7). PMID: 27166974    Free PMC article.
American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory.
Leo Lin, Deepika Sirohi, Joshua F Coleman, H Evin Gulbahce.
Am J Clin Pathol, 2019 Jun 07; 152(4). PMID: 31172196
Review.
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Ian E Krop, Sung-Bae Kim, +7 authors, TH3RESA study collaborators.
Lancet Oncol, 2014 May 06; 15(7). PMID: 24793816
Highly Cited.
Cathepsin B: multiple roles in cancer.
Neha Aggarwal, Bonnie F Sloane.
Proteomics Clin Appl, 2014 Mar 29; 8(5-6). PMID: 24677670    Free PMC article.
Highly Cited. Review.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, +12 authors, EMILIA Study Group.
N Engl J Med, 2012 Oct 02; 367(19). PMID: 23020162    Free PMC article.
Highly Cited.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Kenji Tamura, Junji Tsurutani, +14 authors, Shanu Modi.
Lancet Oncol, 2019 May 03; 20(6). PMID: 31047803
Highly Cited.
Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.
Jian Ruan, Hang Zheng, +3 authors, Rongcheng Luo.
PLoS One, 2014 Nov 11; 9(11). PMID: 25384089    Free PMC article.
Pulmonary toxicity from novel antineoplastic agents.
I Dimopoulou, A Bamias, P Lyberopoulos, M A Dimopoulos.
Ann Oncol, 2005 Nov 18; 17(3). PMID: 16291774
Review.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Kohei Shitara, Hiroji Iwata, +12 authors, Toshihiko Doi.
Lancet Oncol, 2019 May 03; 20(6). PMID: 31047804
Highly Cited.
Trastuzumab emtansine: mechanisms of action and drug resistance.
Mark Barok, Heikki Joensuu, Jorma Isola.
Breast Cancer Res, 2014 Jun 03; 16(2). PMID: 24887180    Free PMC article.
Highly Cited. Review.
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
Alberto Ocaña, Eitan Amir, Atanasio Pandiella.
Breast Cancer Res, 2020 Feb 02; 22(1). PMID: 32005279    Free PMC article.
Review.
2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10-14 December 2019.
Martin Chopra.
Target Oncol, 2020 Jan 26; 15(1). PMID: 31980995
Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance.
Seiichiro Mitani, Hisato Kawakami.
Cancers (Basel), 2020 Feb 14; 12(2). PMID: 32050652    Free PMC article.
Review.
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.
Ricardo L B Costa, Brian J Czerniecki.
NPJ Breast Cancer, 2020 Mar 21; 6. PMID: 32195333    Free PMC article.
Review.
Trastuzumab Deruxtecan: First Approval.
Susan J Keam.
Drugs, 2020 Mar 08; 80(5). PMID: 32144719
Review.
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, +2 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2020 Mar 14; 12(3). PMID: 32164163    Free PMC article.
Review.
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.
Mercedes Nadal-Serrano, Beatriz Morancho, +10 authors, Joaquín Arribas.
Cancers (Basel), 2020 Mar 19; 12(3). PMID: 32183023    Free PMC article.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Review.
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Andriy Marusyk, Michalina Janiszewska, Kornelia Polyak.
Cancer Cell, 2020 Apr 15; 37(4). PMID: 32289271    Free PMC article.
Review.
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Diana Lüftner, Andreas Schneeweiss, +16 authors, Michael P Lux.
Geburtshilfe Frauenheilkd, 2020 Apr 24; 80(4). PMID: 32322108    Free PMC article.
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.
Kwanghee Kim, Wenhuo Hu, +34 authors, Jonathan A Coleman.
Nat Commun, 2020 Apr 26; 11(1). PMID: 32332851    Free PMC article.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Bob T Li, Flavia Michelini, +46 authors, Maurizio Scaltriti.
Cancer Discov, 2020 Mar 28; 10(5). PMID: 32213539    Free PMC article.
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Jordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, Pradip De.
Am J Cancer Res, 2020 May 06; 10(4). PMID: 32368385    Free PMC article.
Review.
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.
Lucía Gandullo-Sánchez, Emily Capone, +3 authors, Atanasio Pandiella.
EMBO Mol Med, 2020 Apr 25; 12(5). PMID: 32329582    Free PMC article.
On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
Igor Dovgan, Anthony Ehkirch, +9 authors, Alain Wagner.
Sci Rep, 2020 May 08; 10(1). PMID: 32376903    Free PMC article.
Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019.
Isabell Witzel, Matteo Lambertini, +2 authors, Volkmar Müller.
Breast Care (Basel), 2020 May 14; 15(2). PMID: 32398990    Free PMC article.
Emerging therapeutic agents for advanced non-small cell lung cancer.
Ruqin Chen, Rami Manochakian, +6 authors, Yanyan Lou.
J Hematol Oncol, 2020 May 26; 13(1). PMID: 32448366    Free PMC article.
Review.
Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.
David M Routman, Bhishamjit S Chera, Gaorav P Gupta.
Cancer J, 2020 Mar 25; 26(2). PMID: 32205535    Free PMC article.
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting.
Salvatore Del Prete, Liliana Montella, +12 authors, Michele Orditura.
Oncotarget, 2020 Jun 18; 11(22). PMID: 32547706    Free PMC article.
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.
Essia Mezni, Cécile Vicier, +3 authors, Anthony Gonçalves.
Cancers (Basel), 2020 Jun 18; 12(6). PMID: 32545895    Free PMC article.
Review.
Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care.
Joanne E Mortimer, Laura Kruper, +10 authors, Yuan Yuan.
J Clin Med, 2020 Jul 01; 9(6). PMID: 32599960    Free PMC article.
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Michelle D Hackshaw, Heather E Danysh, +6 authors, Charles A Powell.
Breast Cancer Res Treat, 2020 Jun 28; 183(1). PMID: 32591987    Free PMC article.
Review.
Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective.
David Dahlgren, Hans Lennernäs.
Molecules, 2020 Jun 25; 25(12). PMID: 32575828    Free PMC article.
Review.
Novel targeted therapies for metastatic breast cancer.
Khalid Jazieh, Ruth Bell, Nayan Agarwal, Jame Abraham.
Ann Transl Med, 2020 Aug 15; 8(14). PMID: 32793751    Free PMC article.
Review.
B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.
Pravin Tp Kaumaya.
Future Oncol, 2020 Jun 23; 16(23). PMID: 32564612    Free PMC article.
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
Eva Blondeaux, Arlindo R Ferreira, +14 authors, Lucia Del Mastro.
ESMO Open, 2020 Aug 21; 5(4). PMID: 32817059    Free PMC article.
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
Gaia Griguolo, Fara Brasó-Maristany, +26 authors, Aleix Prat.
Cancers (Basel), 2020 Jul 18; 12(7). PMID: 32674482    Free PMC article.
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer.
Aena Patel, Nisha Unni, Yan Peng.
Cancers (Basel), 2020 Aug 01; 12(8). PMID: 32731409    Free PMC article.
Review.
Trial watch: IDO inhibitors in cancer therapy.
Julie Le Naour, Lorenzo Galluzzi, +2 authors, Erika Vacchelli.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934882    Free PMC article.
Review.
Toward a More Precise Future for Oncology.
Yonina R Murciano-Goroff, Barry S Taylor, David M Hyman, Alison M Schram.
Cancer Cell, 2020 Apr 15; 37(4). PMID: 32289268    Free PMC article.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Cristina Saura, Mafalda Oliveira, +33 authors, NALA Investigators.
J Clin Oncol, 2020 Jul 18; 38(27). PMID: 32678716    Free PMC article.
Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review.
Wing-Lok Chan, Tai-Chung Lam, +3 authors, Lai-Wan Dora Kwong.
Ther Adv Med Oncol, 2020 Sep 26; 12. PMID: 32973930    Free PMC article.
Review.
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment.
Alberto Juan, Francisco J Cimas, +3 authors, Carlos Alonso-Moreno.
Int J Mol Sci, 2020 Aug 23; 21(17). PMID: 32825618    Free PMC article.
Review.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, +42 authors, E P Winer.
Ann Oncol, 2020 Sep 27; 31(12). PMID: 32979513    Free PMC article.
The emerging role of antibody-drug conjugates in urothelial carcinoma.
Michael Lattanzi, Jonathan E Rosenberg.
Expert Rev Anticancer Ther, 2020 Jun 20; 20(7). PMID: 32552213    Free PMC article.
Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics-The Tale of HER2.
Jeffrey V Leyton.
Antibodies (Basel), 2020 Jul 17; 9(3). PMID: 32668710    Free PMC article.
Review.
NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer.
Takuma Yotsumoto, Keita Maemura, +10 authors, Daiya Takai.
Oncotarget, 2020 Oct 17; 11(39). PMID: 33062195    Free PMC article.
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
Jennifer Y Sheng, Cesar A Santa-Maria, +18 authors, Karen L Smith.
JCO Oncol Pract, 2020 Jul 01; 16(10). PMID: 32603252    Free PMC article.
An overview of antibody-drug conjugates in oncological practice.
Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Helen Gogas, Dimitrios C Ziogas.
Ther Adv Med Oncol, 2020 Oct 23; 12. PMID: 33088347    Free PMC article.
Review.
An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy.
Alberto Juan, Francisco J Cimas, +3 authors, Carlos Alonso-Moreno.
Pharmaceutics, 2020 Aug 29; 12(9). PMID: 32854255    Free PMC article.
Review.
HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.
Hye Jin Lee, Seungho Shin, +4 authors, Kyong Hwa Park.
Cancers (Basel), 2020 Sep 19; 12(9). PMID: 32942617    Free PMC article.
Antibody-Drug Conjugates for Cancer Therapy.
Umbreen Hafeez, Sagun Parakh, Hui K Gan, Andrew M Scott.
Molecules, 2020 Oct 22; 25(20). PMID: 33081383    Free PMC article.
Review.
Molecular Pathogenesis of Pancreatic Ductal Adenocarcinoma: Impact of miR-30c-5p and miR-30c-2-3p Regulation on Oncogenic Genes.
Takako Tanaka, Reona Okada, +7 authors, Naohiko Seki.
Cancers (Basel), 2020 Sep 27; 12(10). PMID: 32977589    Free PMC article.
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Laura L Michel, Andreas D Hartkopf, +27 authors, Tanja N Fehm.
Cancers (Basel), 2020 Oct 22; 12(10). PMID: 33080911    Free PMC article.
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options.
Simon Peter Gampenrieder, Vanessa Castagnaviz, Gabriel Rinnerthaler, Richard Greil.
Cancer Manag Res, 2020 Nov 06; 12. PMID: 33149670    Free PMC article.
Review.
Exaggerated Autophagy in Stanford Type A Aortic Dissection: A Transcriptome Pilot Analysis of Human Ascending Aortic Tissues.
Zeyi Zhou, Yan Liu, +7 authors, Qing Zhou.
Genes (Basel), 2020 Oct 18; 11(10). PMID: 33066131    Free PMC article.
Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates.
Guolan Lu, Naoki Nishio, +6 authors, Eben L Rosenthal.
Nat Commun, 2020 Nov 11; 11(1). PMID: 33168818    Free PMC article.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Hans Tesch, Volkmar Müller, +16 authors, Wolfgang Janni.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173239    Free PMC article.
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Elena Laakmann, Julius Emons, +27 authors, Andreas D Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173241    Free PMC article.
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Hanna Huebner, Christian M Kurbacher, +23 authors, Johannes Ettl.
BMC Cancer, 2020 Nov 13; 20(1). PMID: 33176725    Free PMC article.
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
James Crespo, Hongxia Sun, +6 authors, Bora Lim.
PLoS One, 2020 Nov 13; 15(11). PMID: 33180796    Free PMC article.
Resistance and Overcoming Resistance in Breast Cancer.
Andrea Luque-Bolivar, Erika Pérez-Mora, Victoria Eugenia Villegas, Milena Rondón-Lagos.
Breast Cancer (Dove Med Press), 2020 Nov 19; 12. PMID: 33204149    Free PMC article.
Review.
Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer.
Renata D'Alpino Peixoto, Duilio R Rocha-Filho, +47 authors, Gabriel Prolla.
Ecancermedicalscience, 2020 Nov 20; 14. PMID: 33209117    Free PMC article.
Review.
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
Mariona Baliu-Piqué, Atanasio Pandiella, Alberto Ocana.
Cancers (Basel), 2020 Nov 11; 12(11). PMID: 33167363    Free PMC article.
Review.
Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.
Eirini Thanopoulou, Leila Khader, +5 authors, Valentina Guarneri.
Cancers (Basel), 2020 Nov 14; 12(11). PMID: 33182657    Free PMC article.
Review.
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.
Vic Hart, Hannah Gautrey, John Kirby, Alison Tyson-Capper.
Oncotarget, 2020 Nov 28; 11(46). PMID: 33245725    Free PMC article.
Review.